Pfizer checks if new atirmociclib tablet matches the old one
NCT ID NCT07130097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested whether a new, higher-dose tablet of the cancer drug atirmociclib works the same in the body as the current tablet. Thirty-five healthy adults each received a single dose of both tablet forms after a meal, in random order. The goal was to see if the two formulations are bioequivalent, meaning they are absorbed and processed similarly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atirmociclib (PF-07220060)
What this could lead to
If successful, this study could confirm that a higher-dose tablet works the same as the current one, potentially simplifying manufacturing or dosing.
What could go wrong
This is a small, early-phase study in healthy people, not patients. It only checks how the drug is absorbed, not whether it treats any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States